Detail akcie QuidelOrtho Rg online

Business Summary: QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
Financial Summary: BRIEF: For the fiscal year ended 29 December 2024, Quidelortho Corp revenues decreased 7% to $2.78B. Net loss increased from $10.1M to $2.05B. Revenues reflect North America segment decrease of 14% to $1.62B. Higher net loss reflects Selling, General & Administrative Expens increase of 23% to $740.8M (expense), Other operating expenses increase of 91% to $51.8M (expense).